Preliminary Assessment of Inhaled Nitric Oxide for Acute Vaso-occlusive Crisis in Pediatric Patients with Sickle Cell Disease

JAMA

Volumn 289, Issue 9, 2003, Pages 1136-1142

  Weiner, Debra L ^a,e,f   Hibberd, Patricia L ^b,e   Betit, Peter ^c,e   Cooper, Andrew B ^b   Botelho, Christine A ^b   Brugnara, Carlo ^d,e  

^a Pediatric Emergency   (United States)

^b Clinical Research Program   (United States)

^c Respiratory Care   (United States)

^d Department of Laboratory Medicine ^*  (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHEMOGLOBIN; MORPHINE; NARCOTIC AGENT; NITRIC OXIDE; PLACEBO; VASODILATOR AGENT;

ADHESION; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL OCCLUSION; BLOOD VESSEL TONE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; OXYGEN SATURATION; PAIN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL ANEMIA; THROMBOCYTE ACTIVATION; VISUAL ANALOG SCALE; INHALATIONAL DRUG ADMINISTRATION; PILOT STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NITRIC OXIDE; PAIN MEASUREMENT; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0037420269     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.9.1136     Document Type: Article

References (39)

1. Powars D. Natural history of disease: the first two decades. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. New York, NY: Raven Press; 1994:395-412.
2. Shapiro BS. The acute painful episode. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. New York, NY: Raven Press; 1994:531-542.
3. Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle-cell anemia: a possible determinant of disease severity. N Engl J Med. 1980;302:992-995.
4. Hebbel RP, Vercellotti GM. The endothelial biology of sickle cell disease. J Lab Clin Med. 1997;129:288-293.
5. Belhassen L, Pelle G, Sediame S, et al. Endothelial dysfunction in patients with sickle ceil disease is related to selective impairment of shear stress-mediated vasodilation. Blood. 2001;97:1584-1589.
6. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000;96:2451-2459.
7. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 1997;337:1584-1590.
8. Wun T, Paglieroni T, Talbin F, Welborn J, Nelson K, Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med. 1997;129:507-516.
9. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106:411-420.
10. Gladwin MT, Schechter AN. Nitric oxide therapy in sickle cell disease. Semin Hematol. 2001;38:333-342.
11. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
12. Lopez BL, Davis-Moon L, Ballas SK, Ma XL. Sequential nitric oxide measurements during the emergency department treatment of acute vasoocclusive sickle cell crisis. Am J Hematol. 2000;64:15-19.
13. Morris CR, Kuypers FA, Larkin S, Vichinsky EP, Styles LA. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol. 2000;22:515-520.
14. Reiter CD, Wang X, Tanus-Santos J, et al. Cell-free hemoglobin limits nitric oxide biovailability in sickle-cell disease. Nat Med. 2002;8:1383-1389.
15. Hollman S. Inhibition of nitric oxide synthase induces acute vaso-occlusive crisis in transgenic sickle mice. Paper presented at: American Society of Hematology; December 4, 2000; San Francisco, Calif.
16. Roberts JD, Polander DM, Lang P, Zapol WM. Inhaled nitric oxide in pulmonary hypertension of the newborn. Lancet. 1992;340:818-819.
17. Pepke-Zaba J, Higenbottam TW, Dinu-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet. 1991;338:1173-1174.
18. The Neonatal Inhaled Nitric Oxide Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997;336:597-604.
19. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328:399-405.
20. Kalweit GA, Schipke JD, Godehardt E, Gams E. Changes in coronary vessel resistance during postischemic reperfusion and effectiveness of nitroglycerin. J Thorac Cardiovasc Surg. 2001;122:1011-1018.
21. Atz AM, Wessel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology. 1997;87:988-990.
22. Sullivan KJ, Goodwin SR, Evangelist J, Moore RD, Mehta P. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit Care Med. 1999;27:2563-2568.
23. Butte AJ, Weinstein DA, Kohane IS. Enrolling patients into clinical trials faster using RealTime Recruiting. Proc AMIA Symp. 2000:111-115.
24. Weiner D, Butte A, Hibberd P, Fleisher G. Computerized recruiting for clinical trials in real time. Ann Emerg Med. 2003;41:242-246.
25. Martinez-Ruiz R, Montero-Huerta P, Hromi J, Head CA, Inhaled nitric oxide improves survival rates during hypoxia in a sickle cell (SAD) mouse model. Anesthesiology. 2001;94:1113-1118.
26. Acute Pain Management Guideline Panel. Acute Pain Management: Operative or Medical Procedures and Trauma: Clinical Practice Guideline. Washington, DC: US Dept of Health and Human Services; 1992.
27. Tyler DC, Tu A, Douthit J, et al. Toward validation of pain measurement tools for children: a pilot study. Pain. 1993;52:301-309.
28. Benjamin LJ. Nature and treatment of the acute painful episode in sickle cell disease. In: Steinberg M, Forget B, Higgs D, Nagel RL, eds. Disorders of Hemoglobin: Genetics, Pathophysiology and Clinical Management. Cambridge, England: Cambridge University Press; 2001:671-710.
29. Hardwick WE Jr, Givens TG, Monroe KW, King WD, Lawley D. Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. Pediatr Emerg Care. 1999;15:179-182.
30. Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996;27:485-489.
31. Gallagher EJ, Liebman M, Bijur PE. Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med. 2001;38:633-638.
32. Head CA, Brugnara C, Martinez-Ruiz R, et al. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J Clin Invest. 1997;100:1193-1198.
33. Hrinczenko BW, Schechter AN, Wojtkowski TL, Pannell LK, Cashon RE, Alayash AI. Nitric oxide-mediated heme oxidation and selective beta-globin nitrosation of hemoglobin from normal and sickle erythrocytes. Biochem Biophys Res Commun. 2000;275:962-967.
34. Gladwin MT, Schechter AN, Shelhamer JH, et al. Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J Clin Invest 1999;104:937-945.
35. Gow AJ, Stamler JS. Reactions between nitric oxide and haemoglobin under physiological conditions. Nature. 1998;391:169-173.
36. Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vasoocclusive crisis of sickle cell disease: a randomized controlled trial. JAMA. 2001;286:2099-2106.
37. Glover RE, Ivy ED, Orringer EP, Maeda H, Mason RP. Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol Pharmacol. 1999;55:1006-1010.
38. Gladwin MT, Shelhamer JH, Ognibene FP, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol. 2002;116:436-444.
39. Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol. 2000;111:498-500.